Adare Pharmaceuticals

Oral Drug Delivery Technologies and Drug Development

Make an Enquiry

Princeton Pike Corporate Center , 1200 Lenox Drive, Suite 100, Lawrenceville, 08648,New Jersey, United States of America

More links

Contact Details

Princeton Pike Corporate Center , 1200 Lenox Drive, Suite 100, Lawrenceville, 08648,New Jersey, United States of America

Taste masking and customised drug development

Adare Pharmaceuticals transforms medicines, creating new possibilities for improved patient health.

For decades, the company has successfully overcome complex formulation challenges in specialized and diverse therapeutic categories such as cardiovascular, pain management, gastrointestinal (GI) and central nervous system (CNS), delivering medicines that benefit patients.

Using proprietary technologies, including taste masking and orally disintegrating tablets (ODT), customized drug release, and bioavailability enhancement, Adare has demonstrated the unique ability to transform drug formulations and create novel Rx and over-the-counter (OTC) products.

In addition, Adare can add valuable IP to commercialized products and products in development for business partners worldwide. With global research and development (R&D) and manufacturing facilities, Adare brings complex products from development to commercialization.

Adare Pharmaceuticals

    Since 2009, Adare’s partnerships have resulted in more than 60 product launches in 44 countries.

    Taste masking technology platform

    Adare offers proprietary technologies that provide taste masked products with a pleasant taste and excellent mouth-feel for patient appeal. These technologies include AdvaTab®, Liquitard®, and Microcaps®.

    Customized drug release technology platform

    The customized drug release technology platform consists of various technologies that provide a range of customized release profiles. These drug release profiles can be tailored to optimize a drug’s therapeutic performance by improving efficacy and enhancing safety.

    Patient acceptability and compliance can be increased through less frequent dosing. Adare’s proprietary customized drug release technologies include Diffucaps®, Eurand Minitabs®, and Diffutab®.

    Bioavailability enhancement technology platform

    Adare provides technologies to enable and improve the bioavailability of drugs with low solubility or an extreme pH-dependent solubility profile.

    The resulting formulations can offer effective oral dosing of poorly soluble drug candidates, equivalent therapy at lower doses, faster onset of action, and minimization of food effect. The bioavailability enhancement technologies provided by Adare include Biorise™ and Diffucaps® (solid solution or solid dispersion).

    Collaborations and clients

    The company meets its partners’ business needs by offering technologies and resources for the development of new product formulations or licensing availability of existing product formulations (both Rx and OTC.)

    Adare’s partnership process provides its clients with an experienced management team across all functions and stages of the product development cycle.

    Adare has a multinational infrastructure and integrated R&D and manufacturing facilities in the US and Europe, thereby delivering global solutions to companies in various regions worldwide.

    The company’s global business development and licensing teams aim to provide flexible deal structures to help maximize its partners’ interests.

    Forest Laboratories to Acquire Aptalis

    Aptalis has signed a definitive agreement to be acquired by Forest Laboratories, a leading, fully integrated, specialty pharmaceutical company, for $2.9bn in cash pending required reviews.

    15 Jan 2014

    Aptalis Pharmaceutical Technologies Expands Licensing Team

    Aptalis Pharmaceutical Technologies, a business unit of Aptalis Pharma that develops differentiated products utilizing its oral delivery technologies, today announces that Nigel Ray has been named as the company's Vice President of Global Licensing.

    14 Feb 2013

    Aptalis Announces European Commission Approval for New Formulation of Viread®

    Aptalis Pharmaceutical Technologies, formerly Eurand Pharmaceutical Technologies, focused on developing differentiated oral products utilising its pharmaceutical technologies, today announced that the European Commission has granted marketing authorisation for a new pediatric indication of a new oral granule formulation of Gilead Sciences's Viread® (tenofovir disoproxil fumarate) for HIV-1 infected children aged two to six years of age, and for HIV-1 infected children above six years of age for whom a solid dosage form is not appropriate.

    13 Dec 2012

    PharmaTelevision Interview to Spotlight Aptalis Pharma’s Year in Review

    FDA approvals, revenue gain and organic business growth are just a few of the topics that Aptalis Pharma president John Fraher addresses during an on-air interview with PharmaVentures and PharmaTelevision CEO Fintan Walton. The interview, conducted during BIO 2012 in Boston, reflects Fraher's commentary regarding the integration of companies post Axcan Intermediate Holdings' acquisition of Eurand NV in 2011.

    06 Sep 2012

    Aptalis Wins Appeal Against Generic Version of AMRIX

    Aptalis (previously known as Eurand, Inc.), Cephalon, a wholly-owned subsidiary of Teva Pharmaceuticals Industries Ltd, and Anesta AG prevailed in their appeal to the U.S. Court of Appeals for the Federal Circuit, which reversed a lower court's determination and held that two patents covering the AMRIX muscle relaxant (Cyclobenzaprine Hydrochloride Extended-Release Capsules) are valid.

    24 Apr 2012

    PharmaTelevision Interview to Spotlight Aptalis Pharma President John Fraher

    Company strategy, portfolio development and emerging markets are just a few of the topics that John Fraher, president of Aptalis Pharma, is scheduled to address during an on-air interview with Fintan Walton, CEO, PharmaVentures and PharmaTelevision. The interview is available via on-demand at Pha

    22 Aug 2011

    Eurand to Discuss Strategic Decision-Making at BioEurope Spring

    Steve Ellul, Eurand's director of licensing, will discuss aspects of the company's growth strategy during the session 'Understanding the Drivers for Strategic Decision-Making' at BioEurope Spring in Milan, Italy, on Monday 14 March from 9am to 10.30am local time. The panel of industry

    10 Mar 2011

    Eurand Enters Agreement With Nycomed for ZENPEP in Russia-CIS

    Eurand, a global specialty pharmaceutical company, and Nycomed, a privately owned global pharmaceutical company, have announced an exclusive commercialization, license and supply agreement for Russia and the Commonwealth of Independent States (CIS), as well as Georgia and Mongolia. Financial term

    12 Jan 2011

    Eurand Presents Taste-Masking Technology Webinar

    Eurand, a global specialty pharmaceutical company, has conducted a webinar titled 'The $10 Billion Gap: Leveraging Taste-Masking Technologies to Meet Global Patient Needs', presented by Troy Harmon, vice president of business development, and Andrew Thompson, vice president of commercial operatio

    09 Nov 2010

    Eurand Reports Recent Highlights and Second Quarter 2010 Financial Results

    Eurand, a global specialty pharmaceutical company, today reported revenues for the second quarter of 2010 of €32.9m ($40.5m), an increase of 8%, or 3% in constant currency, from the second quarter of 2009. For the six months ended 30 June 2010, revenues totaled €64m ($78.7m), up

    05 Aug 2010

    Eurand Issued US Patent for ZENPEP (pancrelipase) Delayed-Release Capsules

    Eurand, a global specialty pharmaceutical company, announced today the grant of US Patent No. 7,658,918, titled 'Stable digestive enzyme compositions', by the United States Patent and Trademark Office (USPTO). The patent will provide Eurand with coverage until at least 20 February 2028 on ZENPEP&

    15 Feb 2010
    Adare Pharmaceuticals

    Princeton Pike Corporate Center

    1200 Lenox Drive, Suite 100

    Lawrenceville

    08648

    New Jersey

    United States of America
    +1 609 450 1312 www.adarepharma.com
    Adare Pharmaceuticals

    Via Martin Luther King, 13

    20060, Pessano con Bornago

    Milan

    Bologna

    Italy
    Adare Pharmaceuticals

    845 Center Drive

    Vandalia

    45377

    Ohio

    United States of America